Vaxxas Secures Significant Funding for Vaccine Development
Vaxxas Pty Ltd., an innovator in needle-free vaccine delivery systems, recently announced a remarkable funding achievement of approximately A$90 million. This financial milestone positions the company to enhance its high-density microarray patch (HD-MAP) technology while aiming for commercial viability by 2027.
Funding Structure and Investor Confidence
The recent financing round is noted as one of the largest for a private biotech firm in Australia, incorporating $49.22 million in new Series D equity alongside $40 million in debt facilities. The strong interest from a diverse array of investors reflects their confidence in Vaxxas' innovative technology, with notable participation from SPRIM Global Investments and LGT Crestone as well as existing supporters like OneVentures and Brandon Capital-Hostplus.
Scaling Production and Advancing Technology
This infusion of capital will be pivotal in scaling up production of Vaxxas’ HD-MAP technology, which represents a significant advancement in vaccines. It enables a needle-free approach that minimizes cold storage requirements and supports self-administration, thereby enhancing accessibility and potential uptake across the globe.
Chairman's Perspective on Funding Achievement
Sarah Meibusch, Chair of Vaxxas, remarked on the successful fundraising in a challenging market environment, emphasizing that this achievement demonstrates investor confidence in their mission. She stated that this funding ensures a pathway into the latter half of 2027, focusing on commercializing their groundbreaking technology.
Expert Endorsements and Future Vision
Michael Shleifer, co-founder of SPRIM Global Investments, conveyed his excitement about leading the financing. He believes in the transformative potential of the HD-MAP platform, highlighting the significant commercial opportunities ahead as Vaxxas prepares to bring its technology to the market.
Leadership Transition and Strategic Advisory Roles
In a significant transition, David Hoey, who has served as CEO for 14 years, will take on the role of Strategic Advisor. His leadership has been instrumental in guiding Vaxxas through various growth phases, establishing the company as a frontrunner in innovative vaccine delivery. This shift is seen as foundational for building momentum toward commercialization.
Company Evolution and Future Directions
Under Hoey's stewardship, Vaxxas has accumulated a robust portfolio and forged strategic partnerships that have facilitated over $300 million in funding, significantly impacting the local economy. The leadership change aligns with Vaxxas' strategic focus on ramping up operations and realizing the full potential of its technologies.
About Vaxxas and its Technological Innovations
Vaxxas is at the forefront of developing needle-free vaccine delivery systems with its proprietary technology, the HD-MAP. This innovative patch delivers microdoses of vaccines directly beneath the skin, enhancing the immune response while minimizing dosage requirements and storage constraints. Clinical trials have demonstrated the technology’s capability to improve vaccine delivery methods substantially.
Collaboration and Ongoing Research Efforts
The company continues to expand its collaborative efforts, showcasing its HD-MAP technology in various vaccine programs aimed at tackling prominent health threats like COVID-19, flu, and measles. With clinical trials already involving over 750 participants, Vaxxas is addressing some of the world’s critical health challenges through its innovative approaches.
Frequently Asked Questions
What is Vaxxas' HD-MAP technology?
Vaxxas’ HD-MAP technology refers to a needle-free delivery system that uses a patch to administer vaccines, improving accessibility and storage options.
How much funding did Vaxxas secure?
Vaxxas raised approximately A$90 million, combining equity and debt financing to enhance its vaccine delivery technology.
Who are the major investors in Vaxxas' recent funding round?
SPRIM Global Investments led the funding round, supported by new investor LGT Crestone and existing investors like OneVentures and Brandon Capital-Hostplus.
What are the future plans for Vaxxas?
The company aims to scale production of its HD-MAP technology and fully transition to commercialization by 2027.
Who is leading Vaxxas now?
David Hoey will transition to the role of Strategic Advisor, and a search for a new CEO is well underway to advance the company’s next phase.
Contact:
Amy Miller
amymi@wecommunications.com
+61 431 072 422
